Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. More Details
Imperfect balance sheet with limited growth.
Share Price & News
How has Mesoblast's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MSB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MSB's weekly volatility has decreased from 14% to 6% over the past year.
7 Day Return
1 Year Return
Return vs Industry: MSB underperformed the Australian Biotechs industry which returned -7.4% over the past year.
Return vs Market: MSB underperformed the Australian Market which returned 35.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Mesoblast's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Mesoblast Limited's (ASX:MSB) Shares?
2 months ago | Simply Wall StAnalysts Are More Bearish On Mesoblast Limited (ASX:MSB) Than They Used To Be
2 months ago | Simply Wall StShould Mesoblast (ASX:MSB) Be Disappointed With Their 54% Profit?
Is Mesoblast undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MSB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MSB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MSB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: MSB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MSB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MSB is good value based on its PB Ratio (1.5x) compared to the AU Biotechs industry average (4.7x).
How is Mesoblast forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MSB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MSB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MSB's revenue (66.4% per year) is forecast to grow faster than the Australian market (4.9% per year).
High Growth Revenue: MSB's revenue (66.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MSB is forecast to be unprofitable in 3 years.
How has Mesoblast performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MSB is currently unprofitable.
Growing Profit Margin: MSB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MSB is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.
Accelerating Growth: Unable to compare MSB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (30.3%).
Return on Equity
High ROE: MSB has a negative Return on Equity (-18.91%), as it is currently unprofitable.
How is Mesoblast's financial position?
Financial Position Analysis
Short Term Liabilities: MSB's short term assets ($90.5M) do not cover its short term liabilities ($91.0M).
Long Term Liabilities: MSB's short term assets ($90.5M) exceed its long term liabilities ($77.5M).
Debt to Equity History and Analysis
Debt Level: MSB's debt to equity ratio (17.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MSB's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MSB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MSB has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.6% each year.
What is Mesoblast current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MSB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MSB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MSB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MSB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MSB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Silviu Itescu (63 yo)
Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesobla...
CEO Compensation Analysis
Compensation vs Market: Silviu's total compensation ($USD1.83M) is above average for companies of similar size in the Australian market ($USD884.71K).
Compensation vs Earnings: Silviu's compensation has increased whilst the company is unprofitable.
Experienced Management: MSB's management team is considered experienced (4.3 years average tenure).
Experienced Board: MSB's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.1%.
Mesoblast Limited's company bio, employee growth, exchange listings and data sources
- Name: Mesoblast Limited
- Ticker: MSB
- Exchange: ASX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$1.143b
- Shares outstanding: 657.10m
- Website: https://www.mesoblast.com
Number of Employees
- Mesoblast Limited
- 55 Collins Street
- Level 38
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, h...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 08:11|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.